Synthesis and in vitro cytostatic activity of some new 1,3- (oxytetraethylenoxy)-cyclotriphosphazatriene derivatives

Acta Poloniae Pharmaceutica - Drug Research

Volumn 61, Issue 4, 2004, Pages 267-272

  Porwolik Czomperlik, Iwona ^a   Siwy, Mariola ^a   Sȩk, Danuta ^a   Kaczmarczyk, Bozena ^a   Nasulewicz, Anna ^b   Jaroszewicz, Iwona ^b   Pełczyńska, Marzena ^b   Opolski, Adam ^b  

^a CENTRE OF POLYMER AND CARBON MATERIALS   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Aziridinyl substituents; Crown ether; Cyclophosphazene; Cytostatic activity; Intercalating groups

Indexed keywords

1 [2 [1,3 (OXYTETRAETHYLENOXY) 3,5,5 TRI(CHLORO)CYCLOTRIPHOSPHAZATRIEN 1 YL]AMINOETHYLAMINO]ANTHRAQUINONE; 1 [2 [1,3 (OXYTETRAETHYLENOXY) 3,5,5 TRIS(1 AZIRIDINYL)CYCLOTRIPHOSPHAZATRIEN 1 YL]AMINOETHYLAMINO]ANTHRAQUINONE; 1,3 (OXYTETRAETHYLENOXY) 1 (2 NAPHTHYLOXY) 3,5,5 TRICHLOROCYCLOTRIPHOSPHAZATRIENE; 1,3 (OXYTETRAETHYLENOXY) 1 (2 NAPHTHYLOXY) 3,5,5 TRIS(1 AZIRIDINYL)CYCLOTRIPHOSPHAZATRIENE; 1,3 (OXYTETRAETHYLENOXY) 1,3,5,5 TETRAAZIRIDINOCYCLOTRIPHOSPHAZATRIENE; 1,3 (OXYTETRAETHYLENOXY) 1,3,5,5 TETRACHLOROCYCLOTRIPHOSPHAZATRIENE; 1,3 (OXYTETRAETHYLENOXY)CYCLOTRIPHOSPHAZATRIENE; ANTHRAQUINONE DERIVATIVE; AZIRIDINE DERIVATIVE; CROWN ETHER DERIVATIVE; CYCLOPHOSPHAZENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOSTASIS; DNA ALKYLATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; ORGANOPHOSPHORUS COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13244260948     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Brandt K., Jedliński Z.: Macromol. Chem. (Suppl. 9), 169 (1985).
2. Brandt K., Jedliński Z., Duś D., Radzikowski Cz..: Polym. Med. 18, 170 (1988).
3. Duś D., Brandt K., Gebarowska E., Wojdat E., Jedliński Z., Radzikowski Cz.: Arch. Immunol. Ther. Exp. 37, 539 (1998).
4. Brandt K.: J. Mol. Struct. 243, 163 (1991).
5. Grochowski J., Serda P., Brandt K.: Arzneim.-Fosch/Drug Res. 44, 655 (1994).
6. Brandt K., Porwolik-Czomperlik I., Siwy M., Kupka T., Shaw R.A., Davies D.B. and Bartsch R.A.: Journal of Phenomena and Macrocyclic Chemistry 35, 281 (1999).
7. Brandt K., Kruszyński R., Bartczak T. J., Porwolik-Czomperlik I.: Inorg. Chim. Act. 322, 138 (2001).
8. Labarre J.-F.: Top. Curr. Chem. 102, 1 (1928) (and references therein).
9. Ferguson L.N.: J. Chem. Educ. 52, 688 (1975).
10. Brandt K., Kupka T., Drozd J., Van de Grampel J. C., Meetsma A., Jekel A.: Inorg. Chim. Acta. 228, 187 (1995).
11. Patent Pol. No. 179837, (1995.07.17).
12. Ihara T., Sueda S., Inenaga A., Fukuda R., Takagi M.: Supramol. Chem. 8, 93 (1997).
13. Skehan P., Storeng R., Scudiero D., Monks A., Mcmahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyol M.R.: J. Natl. Cancer. Inst. 82, 1107 (1990).